- Home
- GILD vs PDD Comparison
GILD vs PDD Comparison
Compare GILD & PDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | PDD |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7B | 167.0B |
| IPO Year | 1992 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GILD | PDD |
|---|---|---|
| Price | $124.40 | $120.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | $127.60 | ★ $137.55 |
| AVG Volume (30 Days) | 6.5M | ★ 8.3M |
| Earning Date | 02-10-2026 | 11-18-2025 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 6514.05 | N/A |
| EPS | 6.42 | ★ 9.68 |
| Revenue | $29,087,000,000.00 | ★ $58,790,822,784.00 |
| Revenue This Year | $3.63 | $10.73 |
| Revenue Next Year | $3.10 | $14.94 |
| P/E Ratio | $18.90 | ★ $12.67 |
| Revenue Growth | 2.79 | ★ 12.48 |
| 52 Week Low | $88.57 | $87.11 |
| 52 Week High | $128.70 | $139.41 |
Technical Indicators
Market Signals| Indicator | GILD | PDD |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 59.73 |
| Support Level | $116.88 | $115.18 |
| Resistance Level | $127.41 | $125.36 |
| Average True Range (ATR) | 2.46 | 3.07 |
| MACD | -0.16 | 1.72 |
| Stochastic Oscillator | 67.71 | 79.23 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.